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Colorectal cancer is the third most commonly diagnosed cancer worldwide. Although surgery remains the best
treatment for this disease, adjuvant chemotherapy and radiotherapy are also very important in clinical practice.
However, the notorious refractory lack of responses to radiochemotherapy greatly limits the application of
radiochemotherapy in the context of colorectal cancer.
There is a growing interest in the role that Aurora B may play in colorectal cancer cell survival as well as other
cancer subtypes. In the current study, we sought to ascertain whether blocking of Aurora B signaling machinery by
a small molecule inhibitor, CCT137690, could synergize radiation-induced colorectal cancer cell death. Results
showed that CCT137690 increases the sensitivity of SW620 cells to radiation. Mechanistic studies revealed that
Aurora B-Survivin pathway may be involved in this synergistic effect.
Taken together, our results for the first time show that Aurora B inhibition and radiation exert a synergistic effect,
resulting in enhanced colorectal cancer cell death. This synergistic effect is clinically relevant as lower doses of
radiation could be used for cancer treatment, and could provide significant clinical benefits in terms of colorectal
cancer management, while reducing unwanted side-effects.
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Colorectal cancer (CRC) is the third most commonly di-
agnosed cancer worldwide with over 1.4 million new
cancer cases and 0.6 million estimated deaths every year
[1-3]. The incidence of CRC has rapidly increased in
China and other Asian countries over the last few de-
cades [4-8], and identifying better ways of treating this
cancer is paramount. Although surgery of CRC remains
the best treatment, adjuvant chemotherapy and radio-
therapy are also very important and beneficial treat-
ments for patients [9,10]. After surgery, chemotherapy
and radiotherapy is used to target small cancerous tis-
sues that may be missed during surgery and help to
prevent cancer recurrence.
Aurora kinases (of which there are 3 isoforms: Aurora A,
B and C) are the most important serine/threonine-protein* Correspondence: dryxq186@163.com
†Equal contributors
1Department of Surgical Oncology, Affiliated Hospital of Nanjing University
of Traditional Chinese Medicine, 155 Guangzhou Road, Nanjing 210029,
China
Full list of author information is available at the end of the article
© 2014 Wu et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.kinases which regulate the function of centrosomes, spin-
dles, and kinetochores for proper mitotic progression
[9,11]. Aurora A overexpression has been observed in vari-
ous cancers including colorectal cancers. Baba et. al. re-
ported overexpression of Aurora A protein in 19% of CRC
by immunohistochemistry [12]. High copy amplification of
the Aurora A gene was found in colorectal tumors [13]
and associated with chromosomal instability phenotypes
[14]. In another report, up-regulation of Aurora kinases
were detected in 48.5% (97/200) of patients with colorectal
carcinoma [15]. Similarly, a previous study reported that
the presence of nuclear Aurora B was strongly associated
with lymph node metastasis in colorectal cancer [16]. In
metastatic colorectal cancer, patients with a high expres-
sion level of Aurora B lived significantly shorter compared
with patients with a low expression level [17]. Taken to-
gether, these studies highlight the association of altered
aurora kinases and CRC.
As far as therapeutic options, 5-Fluorouracil (5-FU) re-
mains the most commonly used chemotherapeutic agent
for CRC. However, CRC tumors are highly refractory to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cause of the established roles of Aurora kinases in tumor
initiation and progression, many inhibitors of Aurora ki-
nases have been specifically tested for the treatment of
colorectal cancers in combination with 5-FU, with some
currently in clinical trials [18-22].
Recent studies showed that overexpression of Aurora
kinases might have a role in chemo- and radiotherapy
resistance of cancers [23,24]. Consistent with this notion,
inhibition of Aurora kinases can enhance radiation sen-
sitivity of cancer cells [25,26]. For example, inhibition of
Aurora B sensitizes mesothelioma cells by enhancing
mitotic arrests [27] and also potently suppresses repopu-
lation during fractionated irradiation of human lung
cancer cell lines [28].
CCT137690 is a newly synthesized compound which
has been shown to inhibit the activities of Aurora ki-
nases. IC50 values of CCT137690 are 15 and 25 nM for
Aurora A and B, respectively. Although CCT137690 has
shown promising therapeutic effects on different cancer
cells (especially for colorectal cancer) [29-31], a narrow
safety margin (due to its activity against hERG ion-channel)
may limit its preclinical development [28].
The main cause of treatment failure and recurrence is
resistance of cancer cells to radiation and drugs [32,33].
Since inhibition of Aurora kinases can sensitize cancer
cells to radiotherapy, it is expected that combining radio-
therapy and Aurora inhibition for colorectal cancers may
achieve a synergistic therapeutic effects. Concomitant in-
hibition of Aurora kinases and radiotherapy can also
potentially decrease the dosages of either medicine or
radiation, which in turns can reduce the side effects of
the treatments. Therefore, in our current study we
sought to explore whether the combination of radio-
therapy with CCT137690 may prove efficacious in the
treatment of colorectal cancer cell lines. In this way,
optimized combinatorial treatment may lead to a de-
crease in the requirement of CCT137690 for thera-
peutic benefit.Materials and methods
The authors declared that the current research has been
approved by The Ethics Committee of Nanjing University
of Traditional Chinese Medicine.Reagents
DMEM and fetal bovine serum (FBS) were purchased from
Thermo Fisher Scientific at CHINA (Shanghai, China).
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazoliumbro-
mide (MTT) was obtained from Sigma-Aldrich (Shanghai,
China). Anti-Aurora B antibody and anti-Histone H3
(phospho S10) antibody were obtained from Abcam. Anti-
Survivin antibody was purchased from Cell Signaling.Anti-Histone H3 and GAPDH antibody were obtained
from Santa Cruz Biotechnology.
Cell culture
The human colorectal adenocarcinoma cell lines, SW48
and SW620, were obtained from the American Type
Culture Collection. The cells were maintained in DMEM
supplemented with 10% heat inactivated FBS at 37°C, 5%
CO2, and 95% humidity.
Plasmids and transfection
The full-length cDNA sequence of survivin was amp-
lified from total RNA of SW620 cells by using Reverse
Transcription PCR. The fragment was inserted into
pBABE-Puro vector. The control vector plasmid or the
plasmid encoding survivin was transfected into Phoenix
Retroviral Expression System. Virus was produced and ap-
plied onto target cells according to the standard protocol.
The cells were subjected to drug-selection for 3 days
(0.5 μg/ml of puromycin) to enrich for the desired cells.
Silencing of Aurora A and B in cells
1.5 × 105 cells were seeded in 60-mm plates and incu-
bated for 24 h before transfection. The negative control
siRNA or Aurora A or B siRNA was diluted in Opti-MEM
I Reduced Serum Medium and mixed with Lipofectamine
2000 according to the manufacturer’s instructions. The
mix of DNA and Lipofectamine was added to cells. After
72 hours post-transfection, expression levels of Aurora
genes were determined by Real-time PCR and cells were
used for different assays.
Ionization radiation
Cells were plated in dishes, and then irradiated with
X-ray (104.93 cGy/min at 210 kV and 12 mA) by using an
X-ray irradiator (MBR-1505R2; Hitachi Medico, Tokyo,
Japan) for indicated dosages.
Determination of surviving fraction
2 × 105 cells were plated in a 60-mm dish. 24 hours later,
the cells were exposed to different dosages of ionization
radiation. After a 6-hour recovery, one percent of the cells
were re-plated in a new dish. After 10 days the number of
colonies formed were counted.
Combination effect of radiation and CCT137690
Cells were first treated with CCT137690 at different con-
centrations for 48 hours before they were exposed to dif-
ferent dosages of ionization radiation.
Cell cycle assay
Cells were collected by trypsinization and washed with
PBS, centifuged and then resuspended in 0.4 ml of PBS
and fixed by adding 1ml cold ethanol slowly. Cells were
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centrifuged at 1500 rpm for 5 mins, washed with PBS and
re-suspended in 500 μl staining solution (PBS with 50 μg/
ml PI together with 50 μg/ml RNase A) at 37°C for 30
mins in the dark. Cells were analyzed by flow cytometry.
MTT assay for cell viability
104 cells were seeded into 96-well plates and were treated
to either vehicle (DMSO) or different concentrations of
CCT137690 for 48 hours. Cell viability was determined
and quantified by using MTTassay.
Guava Nexin assay
The Guava Nexin assay was performed following manu-
factory protocol (Millipore). Briefly, attached and sus-
pended cells were all collected. Cells were resuspended in
100 μL of medium and incubated together with 100 μL of
Guava Nexin Reagent for 20 minutes at room temperatureFigure 1 The effects of CCT37690 on proliferation of SW48 and SW62
different concentrations of CCT137690 were measured by using MTT assay
without drug-treatment, SW620 with (430 nM) or without drug-treatment.
mean ± SD, (n = 3).in the dark. Samples then were measured on a Guava
System (Millipore). The data were analyzed by using the
software provided by the company.
Results
In the current study, we sought to identify whether the
combination of radiotherapy and inhibition of Aurora ki-
nases could exert a synergistic inhibitory effect on colo-
rectal cancer cell growth. To test this hypothesis, we
first characterized the sensitivity of two different colo-
rectal cancer cell lines SW-48 and SW-620 to an Aurora
kinase inhibitor, CCT137690. We show that both SW-
48 and SW-620 exhibit dose-dependent responses to
CCT137690 treatment. Moreover, we found that SW-
620 is relatively more resistant to CCT137690 treatment
as compared to SW-48 cells as manifested by a higher
IC50 (430 nM vs 157 nM) (Figure 1A). In addition, when
cells were treated with CCT137690 at their respective0 cells. A, relative cell viabilities of SW48 and SW620 cells treated by
. B, representative figures of cell cycle assays; SW48 with (157 nM) or
C and D, quantification of cell cycle assays; C for SW48, D for SW620,
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lines. There was a lower proportion of cells in G1/G0
and S phase, and a higher proportion of cells in G2/M
and >G2 (Figure 1B-D).
To determine sensitivity of the cell lines to radiother-
apy, GUAVA assay was employed and revealed that radi-
ation was able to induce significant apoptosis in both
SW-48 and SW-620 cell lines (Figure 2B-G). However,
the cell lines displayed different sensitivities to IR: SW-
620 cells exhibits a higher resistance to radiation compared
to SW-48 cells (Figure 2A). Indeed, higher amounts of ra-
diation (3 Gy vs 1 Gy) were required for a similar apoptosis
response in SW-620 cell vs SW-48 cell (Figure 2F and G).
To test whether there is any synergistic effects of radio-
therapy and Aurora kinase inhibition, SW620 cells were
treated with different concentrations of CCT137690 be-
fore they were treated with a low-dose radiation (1 Gy) or
without IR (Figure 3A). Our data suggested that a low-
dose radiation dramatically enhances the inhibitory effect
of CCT137690 on cell growth. 100 nM of CCT137690
has very limited effects on SW620. But surprisingly,Figure 2 The effects of radiation on SW48 and SW620 cells. A, survivin
figures of Guava Nexin assay of SW48 cells, B is for cells without radiation w
of Guava Nexin assay of SW620 cells, D is for cells without radiation while E
Nexin assays, F for SW48, G for SW620, mean ± SD, (n = 3).when combined with radiation, a big proportion of the
cells treated with CCT137690 died through apoptosis
(Figure 3D).
In light of these observations, we ascertained whether
low-dose CCT137690 pretreatment could exert a similar
effect to radiation. As shown in Figure 4A, 100 nM of
CCT137690 pre-treatment dramatically decreases survival
of SW620 cells exposed to radiation. In line with this no-
tion, we also found that CCT137690 pre-treatment dramat-
ically enhances radiation-induced apoptosis (Figure 4B-D).
Since CCT137690 inhibits the activities of both Aurora
A and Aurora B, we wished to clarify whether the syner-
gistic effects of CCT137690 to radiation were due to in-
hibition of Aurora A or Aurora B. We therefore used
siRNA to deplete either Aurora A or Aurora B in SW620
cells (Figure 5A and B). As shown in Figure 5C, only
knockdown of Aurora B dramatically decreases cell sur-
vival following radiation (p < 0.001) while knockdown of
Aurora A does not exert a similar effect (Figure 5C). We
found that radiation induced Aurora B protein expression
and correspondingly higher Aurora B activity, as manifestedg curves of cells after ionization-radiation. B and C, representative
hile C is for cells with 1 Gy of radiation. D and E, representative figures
is for cells with 3 Gy of radiation. F and G, quantification of Guava
Figure 3 Low-dose radiation can increase the sensitivity of SW620 to CCT137690. A, SW620 cells were treated with different concentrations
of CCT137690 for 48 hours before they were treated with (1 Gy) or without radiation. B and C, representative figures of Guava Nexin assays of
cells pre-treated with 100 nM of CCT137690 and then treated with (C) or without (B) radiation. D, quantification of Guava Nexin assays on above
cells, mean ± SD, (n = 3).
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(Figure 5D). In addition, survivin is a reported target of
Aurora B-mediated phosphorylation, and it inhibits cas-
pase activation thereby mediating cell survival through
inhibiting apoptosis [34]. We corroborated these results
by showing that radiation induced higher Aurora B activ-
ity and correspondingly increased survivin protein expres-
sion. However, when cells were additionally treated with
CCT137690 to inhibit activity of Aurora B, the protein
levels of survivin decreased (Figure 5D). Since survivin
is a very important anti-apoptotic protein, the decrease
of survivin may explain the synergistic effects between ra-
diation and CCT137690. Consistent with this notion, sur-
vivin protein expression in SW-48 cells was much lower
than that in SW-620 cells (Figure 5E), which may explain
the different sensitivities of these cells to radiation. To
confirm this point, we managed to over-express survivin
in SW48 cells (Figure 5F). As expected, survivin over-
expression significantly increases the surviving rates ofthe cells after radiation (Figure 5G). To further con-
firm the central role of Aurora B-survivn signaling path-
way in regulating survival upon radiation, we treated
SW620 cells with CCT137690 before radiation, lower sur-
vivin protein level correlates with lower surviving rate
after radiation (Figure 5H and I). In addition, survivin
over-expression in drug-treated cells greatly ameliorates
radiation induced cell death (Figure 5H and I) further
confirmed our hypothesis.
Discussion
Radiotherapy stands a major adjunctive therapeutic op-
tion for colorectal cancer management. Although there
have been intensive investigations on the optimal regi-
men of radiotherapy for this lethal disease, very limited
success have been made during the past several decades.
CRC is notorious for being refractory to both chemo-
therapy and radiotherapy. Thus investigators are particu-
larly interested in characterizing novel molecule targets
Figure 4 Low dosage of CCT137690 sensitizes SW620 cells to radiation. A, SW620 cells (with or without drug treatment (100 nM)) were
exposed to different dosages of radiation. B and C, representative figures of Guava Nexin assays of cells (with (C) or without (B) drug treatment)
exposed to 1 Gy of radiation. D, quantification of Guava Nexin assays on above cells, mean ± SD, (n = 3).
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motherapy in CRC patients. Positive results from these
studies might be clinically important since untoward side
effects from radiotherapy or chemotherapy stands as
major concerns for clinicians in tumor management and
sensitizers of radiochemotherapy may help to reduce dos-
age load and associated toxic side effects.
In light of this notion, we started to search for poten-
tial sensitization targets for radiotherapy of CRC subjects
and we found that there is a recent growing interest in
the role of Aurora B and cancer biology.
In terms of synergistic effect of Aurora B inhibition
and radiotherapy sensitivity, a previous study has shown
that Aurora B inactivation sensitizes mesothelioma cells
[27]. In addition, Aurora B inhibition also potently sup-
presses repopulation during fractionated irradiation of
human lung cancer cells [28].
In the current study, we first show that SW-620 colorec-
tal cancer cells are relatively resistant to Aurora B inhibitionby CCT137690 and to radiation (Figures 1 and 2). How-
ever, we found that the combination of Aurora B inhib-
ition and radiation exerts synergistic effects on cancer cell
growth inhibition. Our results showed that low-dose radi-
ation (1 Gy) greatly exaggerates the growth inhibitory ef-
fect of CCT137690 on SW-620 cells (Figure 3A), as well
as a low-dose of CCT137690 dramatically increases the
sensitivity of cells to radiation (Figure 4A).
Our observations provide a good proof of concept that
both chemotherapy and radiotherapy doses could be
greatly lowered by taking the advantages of synergistic
effects of those two interventions. This could be trans-
lated into the clinic where the expectation is that there
would be less adverse side-effects and better patient
tolerance at lower doses. These findings are especially
important given that CT137690 has a narrow safety
margin.
In terms of understanding of the mechanism by which
inhibiting Aurora B increases radiosensitivity of CRC
Figure 5 The mechanism underlying the synergic action between CCT137690 and radiation. A and B, relative expression of the indicated
genes in SW620 cells treated by control or siRNA of the indicated target, mean ± SD, (n = 3). C, surviving fractions of siRNA transfected cells
(from A, B) with or without radiation. D, Western blot analysis of Aurora B, Ser10-phosphorated Histone H3, Histone H3, survivin and GAPDH in
cells with indicated treatments (IR means 1 Gy, drug = 100 nM). E, the protein levels of survivin and GAPDH in SW48 and SW620 cells. F, protein
levels of survivin and GAPDH in SW48 cells with or without survivin over-expression. G, the surviving fractions of SW48 cells with or without
survivin over-expression upon radiation. H, the protein levels of survivin and GAPDH in cells with or without survivin over-expression under
indicated treatments (IR =1 Gy, drug = 100 nM). I, the surviving fractions of cells described in H, mean ± SD, (n = 3).
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involved (Figure 5). These findings are consistent with
several reports showing the association of Aurora B and
survivin in context of CRC. For example, Tuncel et al.
reported that nuclear Aurora B and cytoplasmic survivin
expression is involved in lymph node metastasis of colo-
rectal cancer [16]. Moreover, Aurora-survivin signaling
machinery has been implicated in other cancers such as
myelodysplasia [35], chronic lymphocytic leukemia [36],
head and neck squamous cell cancer [37]. In this regard,
we observed that forced-expression of survivin dramatic-
ally ameliorates Aurora B-inhibition induced CRC cell
death in the context of radiation (Figure 5I).
Taken together, our results for the first time showed
that Aurora B inhibition, via CCT137690, and radiation
exposure may play synergistic effects in colorectal cancer
death. Taking advantage of this synergistic effect, a lower
dose of radiation exposure and/or chemical exposure is
required for cancer cell death induction, which may have
significant clinical implications for CRC management.
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